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Mice were habituated to the experimental room for at least 45min. They were then placed in the central 23 area of an elevated plus maze (65 cm above the floor, with 2 open and 2 enclosed arms) and allowed to 24 explore the maze for 5 minutes. Maze was cleaned with 5% ethanol between runs. Exploratory behavior, 1 the time spent in each arm or the center, and zone transitions were recorded using the center of the mouse 2 as criterium for zone sojourn. Lux in distal parts of open arms was 12.1-12.2 and 8.7 at the mid junction. 3
Ethovision-software (Noldus) was used to score behavior. 4
Open field and novel object test 5
Light intensity was adjusted to 7 lux in the center of squared boxes. Mice were habituated to the 6 experimental room for more than 30 min before the test and were then placed in the open-field arena. 7
After 10 min a novel object (transparent drinking bottle) was placed in the middle of the arena and mice 8
were again allowed to explore freely for 5 min. Distance travelled and the time spent in the different areas 9 defined in the arena (wall, intermediate and center) were recorded. Ethovision-software (Noldus) was 10 used to score behavior. 11
For the methods and protocols of the following behavioural tests, see the supplementary materials and 12 methods section: marble burying test, fear conditioning tests, forced swim test, resident intruder test, 13 rotarod test, activity cage and saccharine preference test. 14
Immunohistochemistry and imaging 15
For full protocols and antibodies, please refer to supplementary materials. Briefly, 4 µm thick, paraffin-16 embedded sections of paraformaldehyde fixed brains were used for immunohistochemistry after epitope 17 retrieval in trisodium citrate buffer. Immunofluorescence or 3,3'-diaminobenzidine -revelation (DAB) 18 was applied. 19
Statistical analyses 20
Data are presented as means ± SD, except for behavioural tests, in which means ± SEM are presented. 21
Heat maps are based on mean values (of α-synuclein pS129 immunodensities for brain regions). respectively. After surgery, corticosterone/vehicle treatment was continued until shortly before sacrifice 13 ( Fig. 2A) . 14 Treatment with corticosterone induced depressive like phenotypes in the forced swim test (Fig. 2B and  15 suppl. Fig. 2 ) and saccharine preference test (Fig. 2C) . It also elicited pronounced effects on body fat 16 content, body shape and weight gain after surgery (Fig. 2D,E 
PFF injection 7
Elevated corticosterone has previously been shown to affect mood and emotional behavior (Bacq et al., by corticosterone-treatment (Fig. 3A-F) . PFF(C) animals also moved less in the elevated plus maze (Fig.  16   3D) . No significant differences were observed in the open field test, (Fig. 3G-I ). Novel object test (Fig.  17 2J-L) and marble burying test (data not shown), used to assess neophobia and anxiety, were altered 18 neither by PFF injection nor by corticosterone treatment. 19
The involvement of the amygdala in fear-related and aggressive behavior (Coccaro et al., 2007; Rogan et 1 al., 1997) and the high levels of α-synuclein pathology in the amygdala (Fig. 1 ) prompted us to assess 2 potential impairments of these behaviors in presence or absence of α-synuclein pathology and at normal 3 or elevated corticosterone conditions. We observed no differences in a fear conditioning protocol and in a 4 resident intruder aggression test across all conditions (Supplementary Fig. 3 and 4) . 5
Taken together, PFF-injection resulted in a moderately hypo-anxious phenotype one month later, which 6 was reversed by corticosterone-treatment, but did not affect neophobia, fear and aggressive behaviors. highest α-synuclein pS129 densities were observed in the amygdala, prelimbic cortex and substantia nigra 22
maze. A non-significant trend towards hypo-anxiety-like behavior in the elevated plus maze 2 (EPM) of PFF-injected mice was reversed by C-treatment, in the open arms (OA) (A). PFF-3 injected, C-treated mice moved less in the 7 min lasting EPM test as compared to vehicle (V) 4 treated, PFF-injected animals (B). Representative heatmaps visualizing visited areas in the EPM 5 are depicted in (C). Between V-treated groups, PFF-injected animals spent significantly less time 6 in the closed arms (CA) of the EPM, an effect reversed by C-treatment (D). Mice injected with 7

PFF and pretreated with V visited the open arms more often (E) and tended to move to the open 8 arms sooner than C-treated and PFF-injected mice (F). In the open field test, no significant 9 differences in time spent in the center (G), distance travelled (H) or visited area patterns (I) were 10
observed. Despite a trend of lower interest into a novel object of the C-treated PBS group, no 11 significant differences between groups were observed for time spent at the novel object (J) or 12 distance travelled in the field (K). N=17-18 per group for A-F, N=9 per group for G-I. Regular 13
2-way ANOVAs with
for both corticosterone and vehicle treated groups (Fig. 4A) . Interestingly, α-synuclein pS129 signal in the 23 entorhinal cortex was significantly higher in the PFF(C) group as compared to the PFF group, where it 24 was almost absent (Fig. 4B) . Also, in the auditory cortex, α-synuclein pS129 density was significantly 25 higher in PFF(C) mice, whereas differences in other brain regions were small (Fig. 4A) . 26 60 days after PFF-injection the total distance travelled during 3 days in the activity cage was similar 27 across groups ( Supplementary Fig. 5A ). Reduction of motor coordination in the rotarod test of PFF(C) 28 mice was mainly due to corticosterone treatment ( Supplementary Fig. 5B ). While no significant tyrosine-29 hydroxylase (TH) immunoreactive cell loss in the substantia nigra was observed in PFF mice, 1 corticosterone treatment resulted in decreased ipsilateral versus contralateral TH-positive cell numbers 2 (Fig. 4C ). In line with these results, the density of overall nigral TH immunoreactivity was reduced 3 ipsilaterally (hemisphere of injection) in PFF(C) mice ( Supplementary Fig. 5C,D) . α-synuclein pS129 4 immunodensity (Fig. 4B) was similar between PFF and PFF(C) animals. 5
The α-synuclein aggregates were resistant to proteinase K and were detected by antibodies for α-6 synuclein pS129 and for the N-terminal part of α-synuclein (1-20) (Fig. 4E) . These aggregates colocalized 7 with the macro autophagy marker p62 and ubiquitin in the substantia nigra of PFF and PFF(C) mice 8 ( Supplementary Fig. 5E ). 9
Altogether, these results suggest that chronic corticosterone-treatment aggravates neurodegeneration after 10 PFF injection without significantly affecting α-synuclein pathology, as assessed quantitatively (Fig.  11 4A,B) or qualitatively by pS129 immunoreactivity (Fig. 4E and Supplementary Fig. 5E ), in the substantia 12 nigra or general motor behavior ( Supplementary Fig. 5A and B). synuclein mRNA levels and major depression has been reported in patients (Rotter et al., 2019) . Despite 29 the associations between glucocorticoid levels, affective disorders and Parkinson's disease, the 1 relationship of models of (depression-inducing) heightened glucocorticoid and α-synuclein pathology 2 formation and propagation have not been assessed previously. On the basis of these observations, we 3 decided to investigate the interplay of elevated corticosterone and α-synuclein pathology in the amygdala 4 as a potential focal point of these two conditions. 5
(asterisks). Scale bars represent 20 µm (B), 500 µm (C), and 5 µm (E). N=9 per PFF-group (N=3 for 15
PBS groups). Significance levels
To this end, we applied a well-established mouse model of α-synuclein pathology induced by intrastriatal 6 injection of α-synuclein PFFs and combined it with a model of chronic corticosterone treatment, robustly 7 causing depressive-like phenotypes. 8
We report surprisingly modest effects of a-synuclein pathology formation and spreading on behaviors 9 associated with amygdala function at time points of strong α-synuclein pathology in the amygdala. α-10 synuclein pathology induced hypo-anxiety in the elevated plus maze was, however, reversed by chronic 11 corticosterone treatment. Chronic corticosterone treatment elicited clear depressive-like and physiological 12 effects, as depicted in Fig. 2 . These results were confirmed by partial least squares discriminant analysis, 13 which demonstrated in an unbiased way very clear effects of the corticosterone treatment (Suppl. Fig. 6 ). 14 Corticosterone treatment was further associated with aggravated α-synuclein pathology in specific brain 15 regions and dopaminergic cell loss in the substantia nigra after PFF injection. 16
As an important side note, different models of genetically or chronic stress-induced depression (Barkus, The extensive behavioral and neuropathological characterization allowed ample correlative studies 6 (Suppl. Fig. 7 and 8 ), which were followed up by Partial least squares (PLS) regression analysis (Suppl. 7
Fig. 9). 8
Chronic corticosterone treatment surprisingly reversed moderate hypo-anxious-like behaviors, significant 9 for time spent in closed arms in the elevated plus maze, induced by α-synuclein PFF injection. PLS 10 regression analysis revealed that higher α-synuclein pathology in particular in the cingulate cortex and the 11 striatum was correlated with more time spent in the closed arms in this test (Suppl. Fig. 9B ). Respective 12 PLS components indicate this effect to be significantly more pronounced in the corticosterone condition 13 (Suppl. Fig. 9C ), confirming the results of blunted hypo-anxiety. Hypo-anxiety has been described 14 in the other anxiety tests applied. This could be due to the additional exposure to altitude in the elevated 22 plus maze, suggesting that the described hypoanxiety-like effects are more likely to be detectable in 23 stressful conditions, potentially indicating altered coping with stress. 2016). Therefore, we assessed amygdala related emotional and mood behaviors in mice treated 7 chronically with corticosterone, and thus exhibiting depressive-like phenotypes, after induction of α-8 synuclein pathology. 9
We did not observe altered α-synuclein pathology in the amygdala following PFF injection and 10 corticosterone treatment. Despite the severe α-synuclein pathology observed in all PFF-treated animals, 11 most behaviors associated with the amygdala (e.g. fear, aggression) were unaffected. These results 12 suggest that α-synuclein aggregates by themselves do not immediately impair amygdala physiology. This to the contralateral substantia nigra) was not sufficient to trigger motor dysfunction. This is in line with 26 the requirement of massive functional impairment of the dopaminergic nigro-striatal system before 1 occurrence of motor symptoms in patients (Bernheimer et al., 1973) . PLS discriminant analysis differentiated the PFF(C) condition much better from the PFF condition than 5 PFF from PBS. This supports the notion that α-synuclein pathology by itself does not strongly impact on 6 the measured behavioral parameters. Strikingly, α-synuclein pathology at its peak even induced hypo-7 anxious like behavior. In addition, while substantia nigra α-synuclein pathology correlated negatively 8 with distance travelled in the activity cage (similar effects of somatosensory and cingulate cortices), it 9 correlated positively with performance on the Rotarod (note that differences across groups on the Rotarod 10 were due to corticosterone treatment, but not due to PFF treatment, Suppl. Fig. 5B ). Clearly this 11 correlative result has to be interpreted with caution. Should these effects be reproducible, however, this 12 could be due to an initially protective role of α-synuclein pathology in the substantia nigra. Should the 13 pS129-pathology bearing neurons be the vulnerable ones, this could indicate that mice with higher a-14 
Conclusions 7
We report aggravated α-synuclein pathology and neurodegeneration in mice injected with α-synuclein 8
PFFs in a condition of heightened corticosterone, suggesting heightened glucocorticoid levels as a risk 9
factor for the development of the neuropathological hallmarks of Parkinson's disease and potential target 10 for treatment. Taken together, our findings suggest that chronic corticosterone-treatment reduces the 11 ability of the mouse brain to adapt to the proteostatic stress of intrastriatal injection of α-synuclein PFFs, 12 resulting in lower thresholds for α-synuclein pathology handling and nigral neurodegeneration. Further 13 studies aimed at elucidating the vulnerability factors of specific brain regions to α-synuclein pathology, 14 and why at some point resilience fails and neurodegeneration (such as in the substantia nigra) occurs, are 15 needed and will greatly enhance our understanding of the role of α-synuclein pathology in the 16 pathogenesis of Parkinson's disease and synucleinopathies. 17
Based on our results, we propose that α-synuclein pathology in absence of additional clinical (e.g. Kovari, E., Gold, G., Herrmann, F.R., Canuto, A., Hof, P.R., Bouras, C., Giannakopoulos, P., 2003. Lewy 6 body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson's 7 disease. Acta neuropathologica 106(1), 83-88. 8
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